The Indian journal of tuberculosis · 2025
Limited success and high attrition in the 9-month all-oral regimen for MDR-TB: Evidence from a tertiary care setting in Indonesia.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soedarsono, Permatasari Ariani, Agustiyanto Catur, Rampengan Vicky Reinold Christofel
Аннотация
BACKGROUND: The WHO endorses the 9-month all-oral regimen for MDR-TB as a preferred therapeutic option due to its shorter duration, lower cost, and improved adherence compared to the 18-24-month more extended longer regimen. While studies supporting the WHO recommendation report high success rates, in real-world settings, particularly in Indonesian tertiary hospitals, this regimen is often prematurely switched to a longer course. Moreover, success rates for those who continue the 9-month regimen remain relatively low.
OBJECTIVES: This study investigates factors contributing to the premature switch from the 9-month regimen to a longer regimen and evaluates therapeutic outcomes for patients who remain on the 9-month regimen.
METHODS: A retrospective observational study was conducted involving 52 MDR-TB patients who initiated the 9-month all-oral regimen at Dr. Soetomo Hospital, Indonesia, between 2022 and 2024. Reasons for switching to a longer regimen were documented, and therapeutic outcomes, including cure rates, mortality, and loss to follow-up, were assessed among patients who continued the 9-month regimen.
RESULTS: Of 52 patients, 34 (65,38 %) were switched due to resistance to high-dose isoniazid, pyrazinamide, and levofloxacin. Severe nausea and vomiting prompted switching in 13 (25 %), while allergy accounted for 3 cases (5,77 %). Less common reasons included optic neuropathy (1 case, 1,92 %) and increased serum creatinine (1 case, 1,92 %). No switches occurred due to prolonged QT interval or hepatitis. Among the remaining 40 patients, 28 (70 %) were cured, 3 (7.5 %) died, and 9 (22.5 %) were lost to follow-up.
CONCLUSION: Premature switching from the 9-month all oral regimen is mainly due to drug resistance and adverse effects. Patients who remained on the regimen generally had favorable outcomes, though some challenges persist. These findings emphasize the need for timely drug susceptibility testing and better management of adverse effects to optimize the regimen's effectiveness in real-world settings.
OBJECTIVES: This study investigates factors contributing to the premature switch from the 9-month regimen to a longer regimen and evaluates therapeutic outcomes for patients who remain on the 9-month regimen.
METHODS: A retrospective observational study was conducted involving 52 MDR-TB patients who initiated the 9-month all-oral regimen at Dr. Soetomo Hospital, Indonesia, between 2022 and 2024. Reasons for switching to a longer regimen were documented, and therapeutic outcomes, including cure rates, mortality, and loss to follow-up, were assessed among patients who continued the 9-month regimen.
RESULTS: Of 52 patients, 34 (65,38 %) were switched due to resistance to high-dose isoniazid, pyrazinamide, and levofloxacin. Severe nausea and vomiting prompted switching in 13 (25 %), while allergy accounted for 3 cases (5,77 %). Less common reasons included optic neuropathy (1 case, 1,92 %) and increased serum creatinine (1 case, 1,92 %). No switches occurred due to prolonged QT interval or hepatitis. Among the remaining 40 patients, 28 (70 %) were cured, 3 (7.5 %) died, and 9 (22.5 %) were lost to follow-up.
CONCLUSION: Premature switching from the 9-month all oral regimen is mainly due to drug resistance and adverse effects. Patients who remained on the regimen generally had favorable outcomes, though some challenges persist. These findings emphasize the need for timely drug susceptibility testing and better management of adverse effects to optimize the regimen's effectiveness in real-world settings.